在小儿免疫性血小板减少症(ITP)中,个体艾曲波巴浓度存在差异,可能会影响疗效和药物不良反应(ADR)。为了解决这个问题,我们量身定制的艾曲波帕剂量是指浓度,然后随访评估儿科ITP的浓度值。这是一个单一的中心,prospective,观察性研究。调整了艾曲波帕剂量,儿童被分为三组:维持,停药,增加群体。将浓度与其他数据进行比较,以探索指导儿科ITP个体化治疗的浓度值。招募了39名患者,包括维修组的23人,停药组3,增加组13。3例患者因ADRs停药,显着高于维持组患者(t=3.606,p=0.001)。总之,13名患者由于反应不佳而增加了剂量,其浓度和血小板计数明显低于维持组患者(t=2.461,p=0.019;t=4.633,p<0.001)。增加两个月后,达到CR和R的患者人数分别增加2和3,而中位血小板计数显着升高(Z=-2.411,p=0.016)。浓度可作为小儿ITP患者艾曲波帕的个体化治疗的参考指标。
There are variations in individual eltrombopag concentrations that may impact efficacy and adverse drug reactions (ADRs) in paediatric immune thrombocytopaenia (ITP). To solve this problem, we tailored the eltrombopag dosage refer to
concentration, then followed up to assess
concentration value in paediatric ITP. This is a single-centre, prospective, observational study. The eltrombopag dosage was adjusted, and children were divided into three groups: the maintenance, discontinuation, and increase groups.
Concentration and other data were compared to explore
concentration value in guiding the individualized treatment of paediatric ITP. Thirty-nine patients were enrolled, including 23 in the maintenance group, 3 in the discontinued group and 13 in the increase group. 3 patients discontinued eltrombopag due to ADRs, which was significantly higher than patients in the maintenance group (t = 3.606, p = 0.001). In all, 13 patients increased their dosage due to poor response, whose
concentration and platelet count were significantly lower than patients in the maintenance group (t = 2.461, p = 0.019; t = 4.633, p < 0.001). Two months after the increase, the number of patients reaching CR and R respectively increased by 2 and 3, while the median platelet count was significantly raised (Z = -2.411, p = 0.016).
Concentration could be used as a reference index for the individualized treatment of eltrombopag in paediatric ITP.